M&A / Deals Angelini inks $4.1B Catalyst buy to enter US rare disease market BioSpaceCatalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings.Rare DiseaseRead full story pharminent May 7, 2026 (Last updated: May 7, 2026) BioSpace Catalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings. Rare Disease Read full story Post navigation Previous: Bayer plans filings for cardiac amyloidosis imaging agentNext: Novo’s CEO champions “record-breaking start” for Wegovy pill in US market Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
